Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Innovative Pharmaceutical Biotech ( (HK:0399) ).
Starcoin Group Limited has disclosed that the Listing Review Committee of the Hong Kong Stock Exchange upheld an earlier decision to suspend trading in its shares, citing the company’s failure to maintain sufficient operations and assets to justify continued listing. The ruling follows a series of reviews under Listing Rule 13.24 and leaves the group’s listing status under significant pressure, raising concerns for shareholders about the company’s operational scale and compliance profile.
In response, Starcoin has obtained an interim injunction that temporarily blocks implementation of the suspension decision and plans to formally apply for leave to seek judicial review, alongside a request for further interim relief. Trading in the company’s shares remains active pending the court process, but the dispute injects legal and regulatory uncertainty into the stock and underscores heightened oversight of underperforming issuers on the Hong Kong market.
More about Innovative Pharmaceutical Biotech
Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda with limited liability. The group is listed on the Main Board of the Hong Kong Stock Exchange under stock code 399, and its operations have recently come under regulatory scrutiny over the sufficiency of its business activities and asset base.
Average Trading Volume: 47,608,708
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$361.1M
For detailed information about 0399 stock, go to TipRanks’ Stock Analysis page.